



PATENT
Customer No. 22,852
Attorney Docket No. 08702.0009-03000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
LEONARD et al.) Group Art Unit: 1645 (Prior
) Application No. 09/512,930)
Application No.: 10/659,586)
) Examiner: N.M. Minnifield (Prior
Filed: September 11, 2003) Application No. 09/512,930)
)
For: USE OF IL-12 AND IL-12)
ANTAGONISTS IN THE TREATMENT)
OF AUTOIMMUNE DISEASES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO Form 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Applicants enclose copies of the listed documents. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

that the cited documents do not constitute "prior art" under United States law,
Applicants reserve the right to present to the office the relevant facts and law regarding
the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the
patentability of the disclosed invention over the listed documents, should one or more of
the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please
charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 29, 2003

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	10/659,586
Applicant	LEONARD et al.		
Filing Date	September 11, 2003	Group:	To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,547,852	08/20/96	Seiler et al.	435	29	

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	08/087,832		Gately et al.			07/02/93
	08/094,649		Chizzonite et al.			07/19/93
	08/094,713		Chua et al.			07/19/93

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
DE 43 15 127.2	11/19/1993	Germany	A61 K	37/02	Yes, U.S. Patent No. 5,547,852

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Derwent Abstract, WPI Acc No: 1994-350242, DE 4315127.2, Germany
Kelso, et al., "Heterogeneity in Lymphokine Profiles of CD4+ and CD8+ T Cells and Clones Activated <i>in vivo</i> and <i>in vitro</i> " <i>Immunological Reviews</i> , 123:85-114 (1991)

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce